Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.

What Is The Predicted Market Size Of The Methylmalonic Acidemia (MMA) Industry By 2029?

In recent times, there has been a notable rise in the market size of methylmalonic acidemia (mma). The market, which is projected to expand from $9.39 billion in 2024 to $9.94 billion in 2025, is expected to see a compound annual growth rate (CAGR) of 5.9%. Factors such as a higher incidence of metabolic conditions and vitamin deficiencies, increased spending on healthcare, a surge in health awareness, a rising prevalence of inherited disorders, and an increased demand from different end-user sectors have significantly contributed to this growth in the historic period.

In the coming years, the methylmalonic acidemia (mma) market is projected to experience robust growth. The market is set to surge to $12.4 billion in 2029, with a compound annual growth rate (CAGR) of 5.7%. This growth is expected to be driven by several factors, including the expansion of newborn screening programs, increased knowledge among healthcare professionals, advancements in gene therapy, higher investment in research for rare diseases, and the growing availability of specialized treatments. The forecast period will likely also see notable trends such as developments in gene editing technology, advancements in enzyme replacement therapies, more sophisticated diagnostic methods for early detection, the implementation of precision medicine practices, and the wider use of newborn genetic screening programs.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22057&type=smp

Which Factors Are Steering Growth In The Methylmalonic Acidemia (MMA) Market?

The upsurge in metabolic disorders and vitamin shortfalls is projected to boost the expansion of the methylmalonic acidemia (MMA) market in the future. Metabolic disorders comprise a set of conditions where the body struggles to metabolize certain nutrients, produce energy, or control chemical reactions at the cellular level. Vitamin deficiencies are the result of the body’s insufficient supply of specific vitamins, vital for normal functionality. These escalating instances of metabolic diseases and vitamin deficiencies can be attributed to poor diet choices, a sedentary lifestyle, and higher stress levels. Contemporary diet patterns are replete with processed foods, sugars and unhealthy fats, yet deficient in crucial nutrients, causing a deficit of vitamins and minerals. Metabolic disorders and vitamin deficiencies, notably vitamin B12 deficiency, hinder the metabolism of methylmalonyl-CoA, resulting in an build-up of methylmalonic acid and intensifying methylmalonic acidemia (MMA). For example, the National Institutes of Health, a U.S. government agency, stated in November 2024 that the occurrences of vitamin B12 deficiency had risen from 4.6% to 5.2%, accounting for an additional 507 cases between the third and fourth quarters of 2023. As a result, the escalating occurrence of metabolic diseases and vitamin deficiencies stimulate the growth of the methylmalonic acidemia (MMA) market.

Which Segment Accounts For The Largest Share In The Methylmalonic Acidemia (MMA) Market?

The methylmalonic acidemia (mma)market covered in this report is segmented –

1) By Indication: Acidosis; Ketosis; Hyperammonemia; Hypoglycaemia; Hyperglycaemia; Neutropenia; Other Indications

2) By Disorder Type: Homocystinuria; Isolated Methylmalonic Acidurias; Combined methylmalonic Aciduria

3) By Distribution Channel: Hospitals; Pharmacies; Clinics; Other Distribution Channels

Subsegments:

1) By Acidosis: Metabolic Acidosis; Lactic Acidosis

2) By Ketosis: Starvation-Induced Ketosis; Diabetic Ketoacidosis

3) By Hyperammonemia: Acute Hyperammonemia; Chronic Hyperammonemia

4) By Hypoglycemia: Fasting Hypoglycemia; Reactive Hypoglycemi

5) By Hyperglycemia: Transient Hyperglycemia; Persistent Hyperglycemia

6) By Neutropenia: Severe Neutropenia; Cyclic Neutropenia

7) By Other Indications: Failure to Thrive; Developmental Delays; Neurological Symptoms; Renal Dysfunction

Which Disruptive Trends Are Driving Change Across The Methylmalonic Acidemia (MMA) Market?

Companies in the methylmalonic acidemia (MMA) market are focusing on innovative treatments like mRNA-based therapies to improve outcomes by addressing the genetic causes of MMA and enhancing enzyme function to reduce toxic metabolite buildup. mRNA therapies instruct cells to produce specific proteins to prevent or treat diseases including genetic disorders. For example, in June 2024, US-based Moderna, Inc. received FDA approval to include mRNA-3705 in the START pilot program, advancing rare disease treatments. mRNA-3705 is an investigational therapy for MMA caused by MUT deficiency, designed to restore the missing enzyme using mRNA technology. This therapy utilizes Moderna’s proprietary lipid nanoparticle (LNP) delivery system, also employed in mRNA-3927 for propionic acidemia. The FDA granted mRNA-3705 orphan drug, fast track, and rare pediatric disease designations, supporting its accelerated development.

Who Are The Dominant Players In The Methylmalonic Acidemia (MMA) Market Today?

Major companies operating in the methylmalonic acidemia (MMA) market are Moderna Inc., Lonza Group Ltd., Alexion Pharmaceuticals Inc., PTC Therapeutics Inc., Ironwood Pharmaceuticals Inc., Wockhardt Limited, Spectrum Chemical Manufacturing Corp., Asklepios BioPharmaceutical Inc. (AskBio), Selecta Biosciences Inc., BTG International Inc., BridgeBio Pharma Inc., VectivBio Holding AG, Supriya Lifescience Ltd., Recordati Rare Diseases Inc., Agios Pharmaceuticals Inc., AdvaCare Pharma USA LLC, LogicBio Therapeutics Inc., HemoShear Therapeutics LLC, Manus Aktteva Biopharma LLP, Deccan Nutraceuticals Pvt. Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/methylmalonic-acidemia-mma-global-market-report

What Regional Factors Are Accelerating Growth In The Methylmalonic Acidemia (MMA) Market?

North America was the largest region in the methylmalonic acidemia (MMA) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the methylmalonic acidemia (MMA) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=22057&type=smp

Browse Through More Reports Similar to the Global Methylmalonic Acidemia (MMA) Market 2025, By The Business Research Company

Cardiometabolic Diseases Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cardiometabolic-diseases-global-market-report

Comprehensive Metabolic Panel Cmp Testing Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/comprehensive-metabolic-panel-cmp-testing-global-market-report

Dimethyl Carbonate Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/dimethyl-carbonate-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model